<DOC>
	<DOCNO>NCT01188304</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled , parallel group study investigate safety tolerability , effect aleglitazar combination aspirin renal function , renin-angiotensin system platelet aggregation healthy volunteer . Volunteers randomize receive daily dos aleglitazar placebo combination aspirin . The anticipated time study drug 5 week .</brief_summary>
	<brief_title>A Study Aleglitazar Combination With Aspirin Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Aspirin</mesh_term>
	<criteria>Healthy volunteer , age 40 65 year inclusive Body Mass Index ( BMI ) 18 35 kg/m2 inclusive Females childbearing potential must willing use two acceptable method contraception study least 3 month start study Nonsmoker currently smoke less 5 cigarette ( equivalent amount tobacco product ) per day willing able stop smoking period study center Volunteer drink 3 cup coffee , tea soft drink per day willing able stop drinking coffee , tea soft drink period study center Any clinically relevant abnormal laboratory test result screen Volunteer take prescribed , herbal overthecounter medication within 2 week prior first dose A history clinical significant gastrointestinal , cardiovascular , musculoskeletal , endocrine , hematological , psychiatric , renal , hepatic , bronchopulmonary neurological condition lipid disorder A positive test human immunodeficiency virus ( HIV1 HIV2 ) , hepatitis B hepatitis C History intolerance nonsteroidal antiinflammatory drug ( NSAIDs ) aspirin , history gastric duodenal ulceration , personal family history abnormal clotting bleeding</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>